Literature DB >> 16778341

Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis.

Kazuyoshi Imaizumi1, Mihoko Sugishita, Miho Usui, Tsutomu Kawabe, Naozumi Hashimoto, Yoshinori Hasegawa.   

Abstract

Two patients with rheumatoid arthritis (RA) that developed serious infectious complications following anti-TNFalpha therapy (infliximab) are reported. Patient 1 developed tuberculosis with high fever, refractory diarrhea and mediastinal lymphadenopathy. Trans-bronchial needle biopsy was useful to confirm the diagnosis. Patient 2 showed sudden onset of dyspnea with diffuse bilateral lung infiltration caused by pneumocystis jiroveci pneumonia and the diagnosis was confirmed by broncho-alveolar lavage. Physicians should be alerted to infectious complications with atypical presentation and rapid progression in infliximab-treated patients. Invasive diagnostic procedures including fiber-optic bronchoscopy may be necessary early in the course for such cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778341     DOI: 10.2169/internalmedicine.45.1623

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  5 in total

1.  Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia.

Authors:  Matthew R Gingo; Lorrie Lucht; Kieran R Daly; Kpandja Djawe; Frank J Palella; Alison G Abraham; Jay H Bream; Mallory D Witt; Lawrence A Kingsley; Karen A Norris; Peter D Walzer; Alison Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

Review 2.  Pulmonary complications of tumor necrosis factor-targeted therapy.

Authors:  Krishna Thavarajah; Peggy Wu; Elisa J Rhew; Anjana K Yeldandi; David W Kamp
Journal:  Respir Med       Date:  2009-02-07       Impact factor: 3.415

3.  Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha.

Authors:  Osman Elbek; Meral Uyar; Neriman Aydin; Sermin Börekçi; Nazan Bayram; Hasan Bayram; Oner Dikensoy
Journal:  Clin Rheumatol       Date:  2008-12-04       Impact factor: 2.980

4.  Does infliximab increase complications after surgery for inflammatory bowel disease?

Authors:  Stefan D Holubar; Robert R Cima; John H Pemberton
Journal:  F1000 Med Rep       Date:  2009-01-21

5.  Increased dosage of infliximab is a potential cause of Pneumocystis carinii pneumonia.

Authors:  Takuya Iwama; Aki Sakatani; Mikihiro Fujiya; Kazuyuki Tanaka; Shugo Fujibayashi; Yoshiki Nomura; Nobuhiro Ueno; Shin Kashima; Takuma Gotoh; Junpei Sasajima; Kentaro Moriichi; Katsuya Ikuta
Journal:  Gut Pathog       Date:  2016-02-02       Impact factor: 4.181

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.